The Idea

The team from LIfT BioSciences believes they are on the cusp of developing a cure for cancer, based on research, previous trials and their patent-pending technology.

LIfT Bio’s team of experts has decades of experience in clinical development and running trials, and their advisory board contains some of the leading experts in the field.

Their patent-pending platform has been proven in the laboratory with mice, and in multiple in-vitro tests by different investigators.

Since 1970, it’s estimated that over $90 billion has been spent on researching a cure for cancer. One man who has been very important in cancer research is Dr Zheng Cui of Lift Bio Sciences.

While there are thousands of researchers who have worked in cancer research, Dr Cui is unique in his approach to oncology, as he discovered a mouse that was resistant to cancer.

In 1999, during a cancer trial on mice, it was discovered that one mouse was immune to being injected with cancer cells. They tried to inject the mouse with cancer cells again, but no matter how often they did it, the mouse did not contract the disease.

As a result of this astonishing discovery, Dr Cui decided to breed from this mouse, in the hope of creating more cancer immune mice. He was successful, thus creating lots of mice who did not pick up cancer when having it injected into them.

Dr Cui then experimented by injecting white blood cells from cancer-resistant mice into non-resistant mice, who already had cancer. Their tumours shrunk, and the cancer disappeared.

The LIfT Bio team is hoping to make their model central to the fight against cancer in the coming years. The team believes they are onto something quite special, however they require funds to move things forward.

They have won several grants but they are now looking for private investors to allow them to continue their pioneering, and potentially life-saving work.

Have a look at this video above to understand what they are doing.

Login to see more information.

The Market

The market scope for LIfT BioScience products is substantial. For the current line of treatments in development (Donor Derived LIfT) the market encompasses those who suffer from inoperable Pancreatic Cancer (PDAC) in the European Union five (France, Germany, Italy, Spain, United Kingdom) has a market of 48,000 patients at an estimated value of $0.4bn

Further market segments have been identified as follows;

1.    Inoperable Pancreatic Cancer (PDAC) Globally has a market of 280,000 patients at an estimated value of $1.9bn

2.    Other High Unmet Need Orphan Area Solid Tumours: effect over 7 million patients globally with an estimated market value of $20bn.

3.    All Solid Tumours effect 33 million people across the world and equate to an estimated market value of $102bn.

Login to see more information.

Exit Strategy

Login to see more information.

the Numbers

Target: £250,000 Raised so far: £ 98,000.00 Investors: 8
  • Days Left
  • Funded

top investors

Jonathan : £25,000 Colin : £25,000 Robin : £25,000 Derek : £7,500

the Company

Registered number: 9277638 Incorporation date: 23 October 2014 Website: